Hematology / the Education Program of the American Society of Hematology | 2021
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors.
Epperla N, Hamadani M
PubMed
PMID: 34889401
Abstract
Related Articles
CIBMTR Study #: CIBMTR_NA